ClinicalTrials.gg
CompletedNCT02047318IMAGINEUpdated Nov 19, 2021Results posted

An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)

A Phase 2 interventional study of LUM001 (Maralixibat) in Alagille Syndrome, sponsored by Mirum Pharmaceuticals, Inc.. Completed at 3 sites in United Kingdom. Open to participants aged 12 Months to 18 Years. Per ClinicalTrials.gov, last updated 2021-11-19.

Sponsored by Mirum Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
12 Months to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc. — 2 open to participants now, 2 under way, none of them phase 3. Alagille Syndrome · Mirum Pharmaceuticals, Inc..

Started
2013
with 1 other
Phase 2
6 of 10
none open now
Registered
2nd of 10
by date

Among the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc., this one is one of 2 that started in 2013, is one of 6 in phase 2, and was the 2nd registered.

Alagille Syndrome

31 studies on the registry are indexed under Alagille Syndrome; 11 are open to participants now.

Browse Alagille Syndrome studies →

Open to participants now

2 of the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc. are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 10 Alagille Syndrome studies recruiting now, 7 (70%) set no upper age limit and 3 (30%) stop at 75 or younger; 9 take children under 18; none take healthy volunteers.

This study: 12 Months to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc., or all of them as a file.
02

Study summary

The purpose of this extension study is to determine the long-term safety and tolerability of an investigational treatment (LUM001 also known as Maralixibat) in children with ALGS who have completed participation in a core LUM001 treatment protocol. Efficacy will be assessed by evaluating the effect of LUM001 on pruritus, biochemical markers of pruritus, as well as biochemical markers of cholestasis and liver disease.

03

Conditions studied

  • Alagille Syndrome

Browse trials for

04

Who can participate

Ages eligible
12 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Participation for an individual patient is expected to be approximately 72 weeks.

Patients who complete 72 weeks of treatment may be eligible to receive treatment for up to 52 weeks during the follow-up treatment period and patients who completed the 124 weeks of treatment may be eligible to enter the additional long-term follow-up period.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    LUM001 (Maralixibat)

    LUM001 also known as Maralixibat (MRX) administered orally up to twice each day

    Drug: LUM001 (Maralixibat)

Interventions

  • Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 560 micrograms per kilogram (mcg/kg).

06

What researchers measure

Primary outcomes

  1. Change From MRX Baseline to Week 48 in Fasting sBA Levels

    The primary endpoint of this study was the mean change from MRX baseline to Week 48 in fasting sBA level.

    Time frame: MRX baseline to Week 48

Secondary outcomes

  1. Change From MRX Baseline Over Time in Fasting sBA Levels

    This secondary efficacy endpoint is the mean change from MRX baseline over time in fasting sBA levels. Results reported here are the long-term results.

    Time frame: MRX baseline to End of Treatment (maximum exposure was 336 weeks)

  2. Change From MRX Baseline to Week 48 in Pruritus

    This secondary efficacy endpoint is the change from MRX baseline to Week 48 in pruritus as measured by ItchRO(Obs) weekly average morning severity score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).

    Time frame: MRX baseline to Week 48

  3. Change From MRX Baseline Over Time in Pruritus

    This secondary efficacy endpoint is the change from MRX baseline over time in pruritus as measured by ItchRO(Obs) weekly average morning severity score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe). Results reported here are the long-term results.

    Time frame: MRX baseline to End of Treatment (maximum exposure was 336 weeks)

  4. Change From MRX Baseline to Week 48 in Clinician Xanthoma Severity Score

    This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in clinician xanthoma severity scores. It is based on a 0-4 scale to rate the number of lesions present and the degree to which the participant's lesions interfere or limit his or her activities. Clinician xanthoma severity scores range from 0 to 4, with a xanthoma score of zero representing no evidence of xanthomatosis and a score of 4 representing xanthoma so severe that it is disabling. Clinician xanthoma severity scores were not assessed in Study LUM001-302 so mean clinician xanthoma severity score at MRX baseline was calculated from the 5 participants who were assigned to placebo in Study LUM001-302, and analysis of change from MRX baseline is not presented.

    Time frame: MRX baseline to Week 48

  5. Change From MRX Baseline Over Time in Clinician Xanthoma Severity Score

    This secondary efficacy endpoint is the mean change from MRX baseline over time (with Week 252 chosen as the end point, as the last analysis visit with at least 6 participants) in clinician xanthoma severity scores. It is based on a 0-4 scale to rate the number of lesions present and the degree to which the lesions interfere or limit activities. Clinician xanthoma severity scores range from 0 to 4, with a score of zero representing no evidence of xanthomatosis and a score of 4 representing xanthoma so severe that it is disabling. Clinician xanthoma severity scores were not assessed in Study LUM001-302 so mean clinician xanthoma severity score at MRX baseline was calculated from the 5 participants assigned to placebo in Study LUM001-302, and analysis of change from MRX baseline is not presented. Results reported here are the long-term results.

    Time frame: MRX baseline to End of Treatment (maximum exposure was 336 weeks)

  6. Secondary: Change From MRX Baseline to Week 48 in Alkaline Phosphatase

    This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in ALP.

    Time frame: MRX baseline to Week 48

  7. Change From MRX Baseline Over Time in Alkaline Phosphatase

    This secondary efficacy endpoint is the mean change from MRX baseline over time in ALP. Results reported here are the long-term results.

    Time frame: MRX baseline to end of treatment (maximum exposure was 336 weeks)

  8. Change From MRX Baseline to Week 48 in Alanine Aminotransferase

    This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in ALT.

    Time frame: MRX baseline to Week 48

  9. Change From MRX Baseline Over Time in Alanine Aminotransferase

    This secondary efficacy endpoint is the mean change from MRX baseline over time in ALT levels. Results reported here are the long-term results.

    Time frame: MRX baseline to End of Treatment (maximum exposure was 336 weeks)

  10. Change From MRX Baseline to Week 48 in Aspartate Aminotransferase

    This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in AST levels.

    Time frame: MRX baseline to Week 48

  11. Change From MRX Baseline Over Time in Aspartate Aminotransferase

    This secondary efficacy endpoint is the mean change from MRX baseline over time in AST levels. Results reported here are the long-term results.

    Time frame: MRX baseline to End of treatment (maximum exposure was 336 weeks)

  12. Change From MRX Baseline to Week 48 in Gamma Glutamyltransferase

    This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in GGT.

    Time frame: MRX baseline to Week 48

  13. Change From MRX Baseline Over Time in Gamma Glutamyltransferase

    This secondary efficacy endpoint is the mean change from MRX baseline over time in GGT. Results reported here are the long-term results.

    Time frame: MRX baseline to End of Treatment (maximum exposure was 336 weeks)

  14. Change From MRX Baseline to Week 48 in Total and Direct Bilirubin

    This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in total bilirubin and direct bilirubin.

    Time frame: MRX baseline to Week 48

  15. Change From MRX Baseline Over Time in Total and Direct Bilirubin

    This secondary efficacy endpoint is the mean change from MRX baseline over time in total bilirubin and direct bilirubin. Results reported here are the long-term results.

    Time frame: MRX baseline to End of Treatment (maximum exposure was 336 weeks)

07

Results

Posted Nov 19, 2021
Limitations and caveats
Limitations of the trial such as small numbers of subjects analyzed or technical problems leading to unreliable data.

Participant flow

Core Study Period
Participant flow — Core Study Period
MilestoneLUM001 (Maralixibat)
Started19
Received mrx 14 ug/kg/day6
Received mrx 35 ug/kg/day6
Received mrx 70 ug/kg/day6
Received mrx 140 ug/kg/day11
Received mrx 280 ug/kg/day19
Completed7
Not completed12
Withdrew: Did not consent to 52-week follow- up8
Withdrew: Adverse event1
Withdrew: Withdrawal by caregiver3
52-week Follow-up Treatment Period
Participant flow — 52-week Follow-up Treatment Period
MilestoneLUM001 (Maralixibat)
Started6
Completed6
Not completed0
Long-term Follow-up Treatment Period
Participant flow — Long-term Follow-up Treatment Period
MilestoneLUM001 (Maralixibat)
Started7
Received mrx 280 ug/kg/day7
Received 420 ug/kg/day5
Received 560 ug/kg/day5
Completed6
Not completed1
Withdrew: Consent withdrawn by subject1

Outcome measures

PrimaryChange From MRX Baseline to Week 48 in Fasting sBA Levels

The primary endpoint of this study was the mean change from MRX baseline to Week 48 in fasting sBA level.

Time frame:
MRX baseline to Week 48
Reported as:
Mean · μmol/L
Change From MRX Baseline to Week 48 in Fasting sBA Levels
μmol/LCore Study Period: MRX Baseline ValuesCore Study Period: Week 48 Values
Change From MRX Baseline to Week 48 in Fasting sBA Levels261.96 ± 206.839128.32 ± 101.742
Statistical analysis
  • Core Study Period: MRX Baseline Values vs Core Study Period: Week 48 Values · Student's t-test · p = 0.0012 (Data for this analysis were obtained from 19 participants at MRX baseline; 17 of those participants contributed Week 48 data.) · Mean difference (net): -94.4 · 95% CI -145.26 to -43.55
SecondaryChange From MRX Baseline Over Time in Fasting sBA Levels

This secondary efficacy endpoint is the mean change from MRX baseline over time in fasting sBA levels. Results reported here are the long-term results.

Time frame:
MRX baseline to End of Treatment (maximum exposure was 336 weeks)
Reported as:
Mean · μmol/L
Change From MRX Baseline Over Time in Fasting sBA Levels
μmol/LCore Study Period: MRX Baseline ValueWeek 252 Values
Change From MRX Baseline Over Time in Fasting sBA Levels261.96 ± 206.839118.32 ± 76.140
Statistical analysis
  • Core Study Period: MRX Baseline Value vs Week 252 Values · Student's t-test · p = 0.032 (Data for this analysis were obtained from 19 participants at MRX baseline; 6 of those participants contributed Week 252 data.) · Mean difference (net): -141.94 · 95% CI -265.77 to -18.12
SecondaryChange From MRX Baseline to Week 48 in Pruritus

This secondary efficacy endpoint is the change from MRX baseline to Week 48 in pruritus as measured by ItchRO(Obs) weekly average morning severity score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).

Time frame:
MRX baseline to Week 48
Reported as:
Mean · scores on a scale
Change From MRX Baseline to Week 48 in Pruritus
scores on a scaleCore Study Period: MRX Baseline ValueCore Study Period: Week 48 Values
Change From MRX Baseline to Week 48 in Pruritus2.435 ± 0.79521.307 ± 0.6995
Statistical analysis
  • Core Study Period: MRX Baseline Value vs Core Study Period: Week 48 Values · Student's t-test · p = < 0.0001 (Data for this analysis were obtained from 19 participants at MRX baseline; 17 of those participants contributed Week 48 data.) · Mean difference (net): -1.095 · 95% CI -1.464 to -0.726
SecondaryChange From MRX Baseline Over Time in Pruritus

This secondary efficacy endpoint is the change from MRX baseline over time in pruritus as measured by ItchRO(Obs) weekly average morning severity score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe). Results reported here are the long-term results.

Time frame:
MRX baseline to End of Treatment (maximum exposure was 336 weeks)
Reported as:
Mean · scores on a scale
Change From MRX Baseline Over Time in Pruritus
scores on a scaleCore Study Period: MRX Baseline ValueWeek 278 Values
Change From MRX Baseline Over Time in Pruritus2.435 ± 0.79520.952 ± 0.4302
Statistical analysis
  • Core Study Period: MRX Baseline Value vs Week 278 Values · Student's t-test · p = 0.0307 (Data for this analysis were obtained from 19 participants at MRX baseline; 6 of those participants contributed Week 158 data.) · Mean difference (net): -0.958 · 95% CI -1.784 to -0.132
SecondaryChange From MRX Baseline to Week 48 in Clinician Xanthoma Severity Score

This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in clinician xanthoma severity scores. It is based on a 0-4 scale to rate the number of lesions present and the degree to which the participant's lesions interfere or limit his or her activities. Clinician xanthoma severity scores range from 0 to 4, with a xanthoma score of zero representing no evidence of xanthomatosis and a score of 4 representing xanthoma so severe that it is disabling. Clinician xanthoma severity scores were not assessed in Study LUM001-302 so mean clinician xanthoma severity score at MRX baseline was calculated from the 5 participants who were assigned to placebo in Study LUM001-302, and analysis of change from MRX baseline is not presented.

Time frame:
MRX baseline to Week 48
Reported as:
Mean · scores on a scale
Change From MRX Baseline to Week 48 in Clinician Xanthoma Severity Score
scores on a scaleCore Study Period: MRX Baseline ValuesCore Study Period: Week 48 Values
Change From MRX Baseline to Week 48 in Clinician Xanthoma Severity Score0.4 ± 0.550.2 ± 0.73
SecondaryChange From MRX Baseline Over Time in Clinician Xanthoma Severity Score

This secondary efficacy endpoint is the mean change from MRX baseline over time (with Week 252 chosen as the end point, as the last analysis visit with at least 6 participants) in clinician xanthoma severity scores. It is based on a 0-4 scale to rate the number of lesions present and the degree to which the lesions interfere or limit activities. Clinician xanthoma severity scores range from 0 to 4, with a score of zero representing no evidence of xanthomatosis and a score of 4 representing xanthoma so severe that it is disabling. Clinician xanthoma severity scores were not assessed in Study LUM001-302 so mean clinician xanthoma severity score at MRX baseline was calculated from the 5 participants assigned to placebo in Study LUM001-302, and analysis of change from MRX baseline is not presented. Results reported here are the long-term results.

Time frame:
MRX baseline to End of Treatment (maximum exposure was 336 weeks)
Reported as:
Mean · scores on a scale
Change From MRX Baseline Over Time in Clinician Xanthoma Severity Score
scores on a scaleCore Study Period: MRX Baseline ValueWeek 252 Values
Change From MRX Baseline Over Time in Clinician Xanthoma Severity Score0.4 ± 0.550.2 ± 0.41
SecondarySecondary: Change From MRX Baseline to Week 48 in Alkaline Phosphatase

This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in ALP.

Time frame:
MRX baseline to Week 48
Reported as:
Mean · U/L
Secondary: Change From MRX Baseline to Week 48 in Alkaline Phosphatase
U/LCore Study Period: MRX Baseline ValueCore Study Period: Week 48 Values
Secondary: Change From MRX Baseline to Week 48 in Alkaline Phosphatase601.5 ± 232.54596.2 ± 185.20
Statistical analysis
  • Core Study Period: MRX Baseline Value vs Core Study Period: Week 48 Values · Student's t-test · p = 0.8863 (Data for this analysis were obtained from 19 participants at MRX baseline; 17 of those participants contributed Week 48 data.) · Mean difference (net): 7.4 · 95% CI -100.7 to 115.6
SecondaryChange From MRX Baseline Over Time in Alkaline Phosphatase

This secondary efficacy endpoint is the mean change from MRX baseline over time in ALP. Results reported here are the long-term results.

Time frame:
MRX baseline to end of treatment (maximum exposure was 336 weeks)
Reported as:
Mean · U/L
Change From MRX Baseline Over Time in Alkaline Phosphatase
U/LCore Study Period: MRX Baseline ValueWeek 252 Values
Change From MRX Baseline Over Time in Alkaline Phosphatase601.5 ± 232.54430.5 ± 223.56
Statistical analysis
  • Core Study Period: MRX Baseline Value vs Week 252 Values · Student's t-test · p = 0.22 (Data for this analysis were obtained from 19 participants at MRX baseline; 6 of those participants contributed Week 252 data.) · Mean difference (net): -184.3 · 95% CI -522.5 to 153.8
SecondaryChange From MRX Baseline to Week 48 in Alanine Aminotransferase

This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in ALT.

Time frame:
MRX baseline to Week 48
Reported as:
Mean · U/L
Change From MRX Baseline to Week 48 in Alanine Aminotransferase
U/LCore Study Period: MRX Baseline ValueCore Study Period: Week 48 Values
Change From MRX Baseline to Week 48 in Alanine Aminotransferase130.7 ± 59.12174.5 ± 97.28
Statistical analysis
  • Core Study Period: MRX Baseline Value vs Core Study Period: Week 48 Values · Student's t-test · p = 0.0307 (Data for this analysis were obtained from 19 participants at MRX baseline; 17 of those participants contributed Week 48 data.) · Mean difference (net): 51.6 · 95% CI 5.4 to 97.7
SecondaryChange From MRX Baseline Over Time in Alanine Aminotransferase

This secondary efficacy endpoint is the mean change from MRX baseline over time in ALT levels. Results reported here are the long-term results.

Time frame:
MRX baseline to End of Treatment (maximum exposure was 336 weeks)
Reported as:
Mean · U/L
Change From MRX Baseline Over Time in Alanine Aminotransferase
U/LCore Study Period: MRX Baseline ValueWeek 252 Values
Change From MRX Baseline Over Time in Alanine Aminotransferase130.7 ± 59.12175.3 ± 101.17
Statistical analysis
  • Core Study Period: MRX Baseline Value vs Week 252 Values · Student's t-test · p = 0.4934 (Data for this analysis were obtained from 19 participants at MRX baseline; 6 of those participants contributed Week 252 data.) · Mean difference (net): 42.3 · 95% CI -105 to 189.7
SecondaryChange From MRX Baseline to Week 48 in Aspartate Aminotransferase

This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in AST levels.

Time frame:
MRX baseline to Week 48
Reported as:
Mean · U/L
Change From MRX Baseline to Week 48 in Aspartate Aminotransferase
U/LCore Study Period: MRX Baseline ValuesCore Study Period: Week 48 Values
Change From MRX Baseline to Week 48 in Aspartate Aminotransferase127.6 ± 60.03142.4 ± 78.94
Statistical analysis
  • Core Study Period: MRX Baseline Values vs Core Study Period: Week 48 Values · Student's t-test · p = 0.1571 (Data for this analysis were obtained from 19 participants at MRX baseline; 17 of those participants contributed Week 48 data.) · Mean difference (net): 21.2 · 95% CI -9.1 to 51.6
SecondaryChange From MRX Baseline Over Time in Aspartate Aminotransferase

This secondary efficacy endpoint is the mean change from MRX baseline over time in AST levels. Results reported here are the long-term results.

Time frame:
MRX baseline to End of treatment (maximum exposure was 336 weeks)
Reported as:
Mean · U/L
Change From MRX Baseline Over Time in Aspartate Aminotransferase
U/LCore Study Period: MRX Baseline ValueWeek 252 Values
Change From MRX Baseline Over Time in Aspartate Aminotransferase127.6 ± 60.03145.0 ± 56.50
Statistical analysis
  • Core Study Period: MRX Baseline Value vs Week 252 Values · Student's t-test · p = 0.7815 (Data for this analysis were obtained from 19 participants at MRX baseline; 6 of those participants contributed Week 252 data.) · Mean difference (net): 12.2 · 95% CI -94.7 to 119
SecondaryChange From MRX Baseline to Week 48 in Gamma Glutamyltransferase

This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in GGT.

Time frame:
MRX baseline to Week 48
Reported as:
Mean · U/L
Change From MRX Baseline to Week 48 in Gamma Glutamyltransferase
U/LCore Study Period: MRX Baseline ValueCore Study Period: Week 48 Values
Change From MRX Baseline to Week 48 in Gamma Glutamyltransferase476.9 ± 376.85440.5 ± 230.60
Statistical analysis
  • Core Study Period: MRX Baseline Value vs Core Study Period: Week 48 Values · Student's t-test · p = 0.9513 (Data for this analysis were obtained from 19 participants at MRX baseline; 17 of those participants contributed Week 48 data.) · Mean difference (net): -3.9 · 95% CI -136.4 to 128.7
SecondaryChange From MRX Baseline Over Time in Gamma Glutamyltransferase

This secondary efficacy endpoint is the mean change from MRX baseline over time in GGT. Results reported here are the long-term results.

Time frame:
MRX baseline to End of Treatment (maximum exposure was 336 weeks)
Reported as:
Mean · U/L
Change From MRX Baseline Over Time in Gamma Glutamyltransferase
U/LCore Study Period: MRX Baseline ValueWeek 252 Values
Change From MRX Baseline Over Time in Gamma Glutamyltransferase476.9 ± 376.85377.5 ± 163.10
Statistical analysis
  • Core Study Period: MRX Baseline Value vs Week 252 Values · Student's t-test · p = 0.7133 (Data for this analysis were obtained from 19 participants at MRX baseline; 6 of those participants contributed Week 252 data.) · Mean difference (net): -56.7 · 95% CI -431.2 to 317.9
SecondaryChange From MRX Baseline to Week 48 in Total and Direct Bilirubin

This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in total bilirubin and direct bilirubin.

Time frame:
MRX baseline to Week 48
Reported as:
Mean · mg/dL
Change From MRX Baseline to Week 48 in Total and Direct Bilirubin
mg/dLCore Study Period: MRX Baseline ValueCore Study Period: Week 48 Values
Total bilirubin4.47 ± 4.8374.25 ± 5.384
Direct bilirubin3.80 ± 3.8583.21 ± 3.656
Statistical analysis
  • Core Study Period: MRX Baseline Value vs Core Study Period: Week 48 Values · Student's t-test · p = 0.7839 (Data for this analysis were obtained from 19 participants at MRX baseline; 17 of those participants contributed Week 48 data.) · Mean difference (net): 0.16 · 95% CI -1.05 to 1.37
  • Core Study Period: MRX Baseline Value vs Core Study Period: Week 48 Values · Student's t-test · p = 0.5298 (Data for this analysis were obtained from 19 participants at MRX baseline; 17 of those participants contributed Week 48 data.) · Mean difference (net): -0.15 · 95% CI -0.66 to 0.35
SecondaryChange From MRX Baseline Over Time in Total and Direct Bilirubin

This secondary efficacy endpoint is the mean change from MRX baseline over time in total bilirubin and direct bilirubin. Results reported here are the long-term results.

Time frame:
MRX baseline to End of Treatment (maximum exposure was 336 weeks)
Reported as:
Mean · mg/dL
Change From MRX Baseline Over Time in Total and Direct Bilirubin
mg/dLCore Study Period: MRX Baseline ValueWeek 252 Values
Total bilirubin4.47 ± 4.8375.05 ± 6.449
Direct bilirubin3.80 ± 3.8583.53 ± 3.727
Statistical analysis
  • Core Study Period: MRX Baseline Value vs Week 252 Values · Student's t-test · p = 0.8218 (Data for this analysis were obtained from 19 participants at MRX baseline; 6 of those participants contributed Week 252 data.) · Mean difference (net): -0.53 · 95% CI -6.31 to 5.24
  • Core Study Period: MRX Baseline Value vs Week 252 Values · Student's t-test · p = 0.5549 (Data for this analysis were obtained from 19 participants at MRX baseline; 6 of those participants contributed Week 252 data.) · Mean difference (net): -0.52 · 95% CI -2.62 to 1.58

Adverse events

Collected over Treatment-emergent adverse events are AEs with a start date on or after the first dose of study drug and with a start date prior to the last dose of study drug plus 14 days. Maximum exposure was 336 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
14 Microgram Per Kilogram Per Day (mcg/kg/Day)0/6 (0%)0/6 (0%)3/6 (50%)
35 Microgram Per Kilogram Per Day (mcg/kg/Day)0/10 (0%)0/10 (0%)6/10 (60%)
70 Microgram Per Kilogram Per Day (mcg/kg/Day)0/10 (0%)1/10 (10%)3/10 (30%)
140 Microgram Per Kilogram Per Day (mcg/kg/Day)0/13 (0%)0/13 (0%)10/13 (76.9%)
280 Microgram Per Kilogram Per Day (mcg/kg/Day)0/19 (0%)6/19 (31.6%)18/19 (94.7%)
420 Microgram Per Kilogram Per Day (mcg/kg/Day)0/5 (0%)0/5 (0%)3/5 (60%)
560 Microgram Per Kilogram Per Day (mcg/kg/Day)0/5 (0%)1/5 (20%)5/5 (100%)
LUM001 MRX Treatment0/19 (0%)6/19 (31.6%)18/19 (94.7%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
Event14 Microgram Per Kilogram Per Day (mcg/kg/Day)35 Microgram Per Kilogram Per Day (mcg/kg/Day)70 Microgram Per Kilogram Per Day (mcg/kg/Day)140 Microgram Per Kilogram Per Day (mcg/kg/Day)280 Microgram Per Kilogram Per Day (mcg/kg/Day)420 Microgram Per Kilogram Per Day (mcg/kg/Day)560 Microgram Per Kilogram Per Day (mcg/kg/Day)LUM001 MRX Treatment
BradycardiaCardiac disorders0/60/100/100/130/190/51/51/19
Right ventricular failureCardiac disorders0/60/100/100/130/190/51/51/19
Gastrointestinal haemorrhageGastrointestinal disorders0/60/100/100/130/190/51/51/19
Gastrointestinal infectionInfections and infestations0/60/100/100/130/190/51/51/19
Lower respiratory tract infectionInfections and infestations0/60/100/100/130/190/51/51/19
Humerus fractureInjury, poisoning and procedural complications0/60/100/100/130/190/51/51/19
Post procedural haemorrhageInjury, poisoning and procedural complications0/60/100/100/130/190/51/51/19
Pathological fractureMusculoskeletal and connective tissue disorders0/60/100/100/130/190/51/51/19
HypotensionVascular disorders0/60/100/100/130/190/51/51/19
HypoxiaRespiratory, thoracic and mediastinal disorders0/60/101/100/131/190/50/51/19
Most frequent other events
Showing 10 of 127
Most frequent other events
Event14 Microgram Per Kilogram Per Day (mcg/kg/Day)35 Microgram Per Kilogram Per Day (mcg/kg/Day)70 Microgram Per Kilogram Per Day (mcg/kg/Day)140 Microgram Per Kilogram Per Day (mcg/kg/Day)280 Microgram Per Kilogram Per Day (mcg/kg/Day)420 Microgram Per Kilogram Per Day (mcg/kg/Day)560 Microgram Per Kilogram Per Day (mcg/kg/Day)LUM001 MRX Treatment
NasopharyngitisInfections and infestations0/60/100/102/137/190/54/58/19
DiarrhoeaGastrointestinal disorders1/60/101/102/137/190/53/511/19
TonsillitisInfections and infestations0/60/100/100/132/190/53/54/19
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/60/101/101/136/190/53/57/19
Abdominal painGastrointestinal disorders1/62/101/104/1310/190/51/511/19
Upper respiratory tract infectionInfections and infestations0/60/100/103/1310/190/50/511/19
CoughRespiratory, thoracic and mediastinal disorders0/60/100/104/138/190/51/510/19
PyrexiaGeneral disorders0/60/100/102/136/190/51/58/19
HeadacheNervous system disorders0/60/100/100/134/190/52/56/19
LethargyNervous system disorders0/60/100/100/133/190/52/54/19

Baseline characteristics

After a short dose escalation period, participants received MRX 280 ug/kg/day, which consisted of most of their exposure within the study. As such, summaries are presented as a single arm, MRX.

Age, Customized
Age, Customized(Subjects)Core Study Period
<2 years3
2 to 4 years6
5 to 8 years5
9 to 12 years2
13 to 18 years3
Sex: Female, Male
Sex: Female, Male(Participants)Core Study Period
Female9
Male10
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Core Study Period
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American1
White16
More than one race1
Unknown or Not Reported0
08

Study locations

3 sites
  • Birmingham Children's Hospital
    Birmingham, West Midlands B4 6NH, United Kingdom
  • Leeds Teaching Hospital NHS Trust
    Leeds, West Yorkshire LS1 3EX, United Kingdom
  • Kings College Hospital
    London, SE5 9RS, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2013 to primary completion in Jun 2020, 77 months.

Results were first posted in Nov 2021, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2014
First posted
Jan 28, 2014
StartActual
Dec 20, 2013
Primary completionActual
Jun 17, 2020
CompletionActual
Jun 17, 2020
Results first posted
Nov 19, 2021
Last update
Nov 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02047318
Responsible party
Sponsor
First posted
Jan 28, 2014
Start date
Dec 20, 2013
Primary completion
Jun 17, 2020
Completion
Jun 17, 2020
Results posted
Nov 19, 2021
Last update
Nov 19, 2021

Study contacts

Study Director
study director · Mirum

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maralixibat

Start the discussion